PYC Chart looks the goods, page-149

PYC already has US$1-2b of projected income p.a. in 18-24 month when VP-001 is commercialized. Quickly followed by PYC-001 and VP-002 racking in another US$5b and US$1b of annual earnings respectively, year after year.

The company certainly isn’t suggesting this.

In its June presentation, the company set out an indicative timeline for the development of VP-001 (Retinitis Pigmentosa type 11). In more recent presentations, the suggestion is that the IND for VP-001 might be submitted in Q2 2022. The company’s June timeline suggests a wait from that point of approximately 3.5 years before approval. Therefore, revenues from VP-001, if it makes it to approval, shouldn’t be expected before late 2025 - at least 5 years.

VP-002 (Autosomal Dominant Optic Atrophy) is likely to be the next drug candidate to market, imo. The company suggests an IND might be ready for submission in mid-2023. If VP-002 were to follow the same timeline as VP-001, revenue might come by the end of 2026.

PYC-001 (Diabetic Retinopathy) targets a much more prevalent condition and is therefore likely to require both more and larger trials and have a longer FDA review period. The duration of other Diabetic Retinopathy trials suggests a minimum of 5 years would be required for human trials. The company currently anticipates IND submission in mid-2023. With luck, marketing approval might come in 2029.